Assessing frequency and clinical outcomes of BRCA mutated ovarian cancer in Saudi women
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Assessing frequency and clinical outcomes of BRCA mutated ovarian cancer in Saudi women ; volume:22 ; number:1 ; day:3 ; month:1 ; year:2022 ; pages:1-9 ; date:12.2022
BMC cancer ; 22, Heft 1 (3.1.2022), 1-9, 12.2022
- Urheber
-
Agha, Naela
Alshamsan, Bader
Al-Farsi, Sharifa
Ateya, Heba Aly
Almugbel, Fahad A.
Alotaibi, Hazem Abdullah
Omar, Ayman
Mohamed, Amgad Shahin
Alharthy, Hanan
Elhassan, Tusneem
Salem, Hany
Alhusaini, Hamed
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-021-09123-6
- URN
-
urn:nbn:de:101:1-2022042120075213272752
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:28 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Agha, Naela
- Alshamsan, Bader
- Al-Farsi, Sharifa
- Ateya, Heba Aly
- Almugbel, Fahad A.
- Alotaibi, Hazem Abdullah
- Omar, Ayman
- Mohamed, Amgad Shahin
- Alharthy, Hanan
- Elhassan, Tusneem
- Salem, Hany
- Alhusaini, Hamed
- SpringerLink (Online service)
Ähnliche Objekte (12)
MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer
Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study
BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing
Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
BRCA germline mutation test for all woman with ovarian cancer?
Promoter hypomethylation, especially around the E26 transformation-specific motif, and increased expression of poly (ADP-ribose) polymerase 1 in BRCA-mutated serous ovarian cancer
Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
Hereditary Breast and Ovarian Cancer Syndrome (BRCA) Gene: Concept, Pathways, Therapeutics, and Future
Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors
Variation of mutant allele frequency in NRAS Q61 mutated melanomas
Transcriptome Patterns of BRCA1- and BRCA2- Mutated Breast and Ovarian Cancers
MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer
Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study
BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing
Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
BRCA germline mutation test for all woman with ovarian cancer?
Promoter hypomethylation, especially around the E26 transformation-specific motif, and increased expression of poly (ADP-ribose) polymerase 1 in BRCA-mutated serous ovarian cancer
Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
Hereditary Breast and Ovarian Cancer Syndrome (BRCA) Gene: Concept, Pathways, Therapeutics, and Future
Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors
Variation of mutant allele frequency in NRAS Q61 mutated melanomas
Transcriptome Patterns of BRCA1- and BRCA2- Mutated Breast and Ovarian Cancers
MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer
Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study
BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing
Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
BRCA germline mutation test for all woman with ovarian cancer?
Promoter hypomethylation, especially around the E26 transformation-specific motif, and increased expression of poly (ADP-ribose) polymerase 1 in BRCA-mutated serous ovarian cancer
Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
Hereditary Breast and Ovarian Cancer Syndrome (BRCA) Gene: Concept, Pathways, Therapeutics, and Future
Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors
Variation of mutant allele frequency in NRAS Q61 mutated melanomas